

Research Notes D-61

Arm & Hammer Animal Nutrition



CELMANAX Liquid and its effect on Cryptosporidiosis infected dairy calves


STUDY OVERVIEW

- This study¹ was conducted to evaluate the effects of supplementing CELMANAX™ Liquid on clinical recovery in *Cryptosporidium parvum*-infected dairy calves
- The study included 16 calves, ranging from 10 to 12 days old, that demonstrated clinical signs of cryptosporidiosis
- The trial lasted 5 days.
- Calves were randomly assigned to one of two treatment groups:
 - Control
 - CELMANAX Liquid – fed twice daily for 5 days with pasteurized whole milk at rate of 4 ml/calf twice daily
- Fecal samples were taken at the start and end of the trial
- Samples were analyzed for oocyst enumeration, fecal consistency scores (1=normal, 5=watery) and dehydration scores (1=normal, 5=emaciated)

RESULTS

- Oocyst numbers for calves receiving CELMANAX were reduced threefold by day 15, but variation was high and the difference was not statistically significant
- Fecal scores were lower ($P=0.03$) for calves supplemented with CELMANAX Liquid compared to the control
- Dehydration scores were lower ($P=0.01$) for calves supplemented with CELMANAX Liquid compared to the control

FIGURE 1: Effect of CELMANAX on crypto oocysts shedding in sick calves



CONCLUSION

- Calves supplemented with CELMANAX™ Liquid shed fewer oocysts and had significantly improved fecal and dehydration scores compared to those fed the control diet

FIGURE 2: Effect of CELMANAX on fecal scores in crypto infected calves





FIGURE 3: Effect of CELMANAX on dehydration scores in crypto infected calves



Animal Nutrition



1 Data published in J Anim Sci 2009 Vol. 87, E-Suppl. 2/J Dairy Sci Vol. 92, E-Suppl. 1

© 2016 Church & Dwight Co., Inc. ARM & HAMMER™ and the ARM & HAMMER logo and CELMANAX™ are trademarks of Church & Dwight Co., Inc. CE2597-1216